Recent evidence has confirmed that miR-19a can inhibit CRC angiogenesis by targeting KRAS and VEGFA [51] and that miR-181d reduces cell proliferation, migration and invasion by triggering PEAK1, a downstream regulator in EGFR/KRAS pathway [52]. The gene discussed is KRAS; the disease is colorectal carcinoma.